Moderna, Korea University Team on mRNA Hantavirus Vaccine

Moderna and Korea University announced in July 2024 a partnership to develop an mRNA vaccine for hantavirus, a hemorrhagic fever endemic to East Asia. The collaboration combines Moderna's manufacturing and regulatory expertise with Korea University's regional disease knowledge. Early mouse studies suggest mRNA candidates trigger stronger immune responses than traditional inactivated vaccines, signaling the technology's expansion beyond pandemic use.